Fig. 1
From: Unraveling EGFR-TKI resistance in lung cancer with high PD-L1 or TMB in EGFR-sensitive mutations
The relationship between TMB and clinical indicators. (A) Lung cancer pathological type; (B) Age at diagnosis in years; (C) Gender; (D) EGFR mutation status; (E) PD-L1 expression level; and (F) EGFR mutation status and PD-L1 expression level. “ns”, “*”, “**”, “***” and “****” indicate P > 0.05, P < 0.05, P < 0.01, P < 0.001 and P < 0.0001, Wilcoxon test. LUAD for adenocarcinoma; LUSC for squamous cell carcinoma